Orchiectomy combined with cyproterone acetate or prednisone in the treatment of advanced prostatic carcinoma. A randomized clinical and endocrine study.
Thirty-four previously untreated patients with advanced prostatic carcinoma, histologically graded as being of intermediate differentiation, were randomized in three groups. All patients were treated with primary orchiectomy, group I was observed without additional therapy, group II treated with oral administration of prednisone and group III treated with cyproterone acetate per os. The clinical results with the combination orchiectomy and prednisone was encouraging both when initial and secondary remissions were considered. Cyproterone acetate treatment induced a highly significant raise in plasma prolactin, a fact which may explain the less favourable clinical results in this group.
D000230:Adenocarcinoma / Q000188:drug therapy* / Q000628:therapy; D000368:Aged; D002369:Castration; D002986:Clinical Trials as Topic; D003534:Cyproterone / Q000031:analogs & derivatives* / Q000627:therapeutic use; D017373:Cyproterone Acetate; D006801:Humans; D008297:Male; D011241:Prednisone / Q000627:therapeutic use*; D011471:Prostatic Neoplasms / Q000188:drug therapy* / Q000628:therapy; D011897:Random Allocation
D017373:Cyproterone Acetate; D003534:Cyproterone; D011241:Prednisone